BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 21339541)

  • 1. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
    Ndraha S; Hasan I; Simadibrata M
    Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
    Chen MF; Li RC; Chen CH; Gao XC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
    Ndraha S; Simadibrata M
    Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
    Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
    J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The dietary protein contribution and hepatic encephalopathy in cirrhosis].
    Zavaglia C; Brivio M; Losacco E; Onida L
    Recenti Prog Med; 1992 Apr; 83(4):218-23. PubMed ID: 1626117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
    Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
    Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Protein catabolism and malnutrition in liver cirrhosis - impact of oral nutritional therapy].
    Norman K; Valentini L; Lochs H; Pirlich M
    Z Gastroenterol; 2010 Jul; 48(7):763-70. PubMed ID: 20607635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
    Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
    Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study.
    Malaguarnera M; Risino C; Cammalleri L; Malaguarnera L; Astuto M; Vecchio I; Rampello L
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):762-70. PubMed ID: 19357525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Branched-chain amino acids and their ketoanalogs: therapeutic uses in patients with chronic liver or kidney failure].
    Bode JC
    Internist (Berl); 1985 Jul; 26(7):388-98. PubMed ID: 3897107
    [No Abstract]   [Full Text] [Related]  

  • 14. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M; Yang Z; Qi X; Fan D; Han G
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral administration of branched-chain amino acids in the treatment of hepatic disease].
    Qian SC
    Zhonghua Yi Xue Za Zhi; 1986 Sep; 66(9):525-7, 574. PubMed ID: 3098373
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis.
    Kawaguchi T; Taniguchi E; Sata M
    Nutr Clin Pract; 2013 Oct; 28(5):580-8. PubMed ID: 23945292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diets in Encephalopathy.
    Abdelsayed GG
    Clin Liver Dis; 2015 Aug; 19(3):497-505. PubMed ID: 26195204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nutrition in hepatic encephalopathy.
    Schulz GJ; Campos AC; Coelho JC
    Curr Opin Clin Nutr Metab Care; 2008 May; 11(3):275-80. PubMed ID: 18403924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis].
    Moĭseienko VO; Manzhaliĭ EH; Solonovych OS; Nykula TD
    Lik Sprava; 2014 Nov; (11):39-47. PubMed ID: 25528831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.